+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer



Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer



Chinese Journal of Cancer Research 30(3): 315-326



Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.

(PDF emailed within 1 workday: $29.90)

Accession: 055351388

Download citation: RISBibTeXText

PMID: 30046226


Related references

Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast 32: 119-125, 2017

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. International Journal of Cancer 136(9): 2158-2165, 2015

A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6. Cancer Science 107(7): 882-889, 2017

Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clinical Cancer Research 21(5): 1098-1105, 2016

By the numbers: does circulating tumor cell enumeration have a role in metastatic breast cancer?. Journal of Clinical Oncology 32(31): 3479-3482, 2014

Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China. Medical Science Monitor 23: 3071-3079, 2018

Natural killer cell and killer cell activities and circulating immune complexes in patients with breast cancer. Indian Journal of Medical Research 85(APR): 404-414, 1987

Natural killer cell & killer cell activities & circulating immune complexes in patients with breast cancer. Indian Journal of Medical Research 85: 404-414, 1987

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. American Journal of Nuclear Medicine and Molecular Imaging 6(2): 120-127, 2016

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research 23(1): 88-96, 2016

Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clinical Cancer Research 19(6): 1596-1602, 2013

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Communications 39(1): 1-1, 2019

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research 21(12): 2771-2779, 2016

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Research 16(5): 445, 2015

Hot Spot and Whole-Tumor Enumeration of CD8 + Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. Clinical Breast Cancer 18(6): 451-458.E1, 2018